MEDSITOL SACHETS: Restores fertility, regulates menstruation, Prevents endometrial hyperplasia and endometrial cancer.
Keywords:
Medsitol Sachets, Ovulation, Hormonal disturbances, PCOSAbstract
Polycystic ovary syndrome (PCOS) is a disorder characterized by hormonal imbalance, irregular menstrual periods, excess hair growth, and obesity. Women with PCOS typically have numerous cysts on the ovaries. PCOS is the most common hormonal disorder among women of reproductive age, affecting an estimated 5–10 percent of Indian population. In PCOS, the body produces an excess number of androgens, and the ratio of luteinizing hormone to follicle-stimulating hormone is abnormally high. Ovulation occurs less frequently, or the ovaries don’t release eggs at all. In the absence of ovulation, the menstrual cycle is irregular or absent, and cysts containing the immature eggs form on the ovaries. This causes the ovaries to enlarge. Research suggests that PCOS may result from excess insulin, which boosts male hormone production (androgens), leading to menstrual cycle disturbances, acne, and coarse hair growth. Genetic factors may also be at play since this occurs more commonly in those with a family history. Early diagnosis and treatment of PCOS is important to improving quality of life and reducing the risk of long-term complications, such as diabetes and heart disease. Research Studies concluded that medsitol Sachets may regulate menstrual cycles and improve ovulation, medsitol sachets appears to be effective in improving hormonal disturbances of PCOS.The present paper Reviews the Role of medsitol sachets developed by R&D cell of Lactonova Nutripharm Pvt Ltd. Hyderabad in hormonal disturbances of PCOS,to regulate menstrual cycles and to improve ovulation, Restores fertility, regulates menstruation, prevents endometrial hyperplasia and endometrial cancer.
Downloads
Published
Issue
Section
License
Rights and reuse terms depend on the individual article record. Articles accepted on or after 8 September 2026 are licensed under Creative Commons Attribution 4.0 International (CC BY 4.0), provided appropriate credit is given, a link to the licence is supplied and changes are indicated. Earlier content remains governed by the rights and licence notice applicable to that article and is not retrospectively relicensed by this policy. Third-party material identified under a different notice is excluded from the journal licence.

